Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)Emma M. Kileel, Steven Grinspoon, Carl J. Fichtenbaum et al.|Clinical Infectious Diseases|2023Cited by 8
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M. Kileel, Heather J Ribaudo, Carlos Malvestutto et al.|The Lancet HIV|2026Cited by 2